History of Infection Prior to Hematopoietic Stem Cell Transplant in the Recipient as a Risk Factor to Develop Acute Graft versus Host Disease

Alberto Olaya-Vargas1*, Iván Castorena-Villa2, Martin Pérez-García1, Gerardo Lopéz-Hernández1, Nidesha Ramírez-Uribe1, Haydeé Salazar-Rosales1

1Hematopoietic Stem Cell Transplant and Cell Therapy Program, National Institute of Pediatrics (INP), Mexico City, México
2Hematopoietic Stem Cell Transplant and Cell Therapy Program, Hospital Infantil de México Federico Gomez, Instituto Nacional de Salud, México City, México

Email: *alberto.olaya@yahoo.com.mx

Abstract

Background: Acute graft-versus-host disease (aGVHD) is the most frequent and severe complication after allogeneic hematopoietic stem cell transplantation (HSCT). Objective: To determine if a history of prior infection in the allogeneic HSCT recipient is a risk factor to develop aGVHD. Methods: A retrospective cohort study based on data collected from the Department of Hematopoietic Stem Cell Transplantation at the Instituto Nacional de Pediatría (INP) from January 1998 to December 2016 was performed to identify if prior infection was a predictive risk factor for aGVHD. Results: 27 patients developed aGVHD (36.4%). Median time to aGVHD presentation was 82 days (9 to 273 days). Most patients developed grade III aGVHD. Following the multivariate analysis peripheral blood > bone marrow (OR 12.3; p < 0.001), cell dose > 8.3 × 10^6/kg (OR 7.1; p = 0.05), peripheral blood (OR: 11.4; p < 0.001), infection 3 months prior to allogeneic transplant (OR: 4.5; p < 0.03) and CMV infection in the recipient (OR: 4.68; p < 0.03) were significant. Conclusions: Either bacterial infection or CMV infection in the recipient was significant risk factor within the aGVHD recipients; it is important to consider these factors for patients that are going to receive an allogeneic HSCT.

Keywords

Allogeneic HSCT, Complications, Acute GVHD, HSCT Infections
1. Introduction

Acute graft-versus-host disease (aGVHD) is the most frequent and severe complication after allogeneic hematopoietic stem cell transplantation (HSCT) [1]. Its incidence has been reported from 30% - 80%; the range of presentation is due to different risk factors within each patient. Previous history of infection in the allogeneic HSCT host activates the immune response and could be an independent risk factor to induce aGVHD.

Jaing et al., recently published information that links CMV infection as a risk factor for the development of aGVHD grades III and IV; on the other hand, Sano et al., reported that bloodstream infection is also a risk factor for the development of aGVHD according to an analysis performed retrospectively in patients who had systemic infections in the first 30 days post-transplant [1] [2] [3].

Our objective was to determine if a history of prior infection in the allogeneic HSCT recipient is a risk factor to develop aGVHD.

2. Materials and Method

2.1. Eligibility of Patients

This is a retrospective cohort study based on data collected from the allogeneic transplant performed at the Department of Hematopoietic Stem Cell Transplantation at the Instituto Nacional de Pediatría (INP) registered in a database, from January 1998 to December 2016. We identified 144 patients in the study period, of which 115 patients were eligible for the study because they received an allogeneic transplant, of these 115 cases, 41 patients were excluded due to that they did not achieve the graft for the reasons that are specified in the results section, leaving 74 patients for the final analysis.

2.2. Classification by Degrees of aGVHD

For the purpose of the study aGVHD was staged using the scores by Glucksberg in 1974, and then modified at the Keystone Conference in 1994. When diagnosis was uncertain a biopsy was obtained and diagnosis was confirmed by a pathologist.

2.3. Study Variables and Definitions

The main variables that were the objective of the study were: infections prior to the allogeneic HSCT was defined as the presentation of any infection 3 months prior to the procedure or history of cytomegalovirus (CMV) infection, confirmed by serology(antigens) or CMV viral load by real time polymerase chain reaction (RT-PCR) (positive: >1000 copies/mL).

Other variables analyzed were several classic risk factors for the development of aGVHD as the type of progenitor cell source defined by the site of obtaining hematopoietic progenitor cells (peripheral blood, bone marrow, umbilical cord blood), a high cellular dose defined as a dose > 8 x 10^6/kg of receptor weight, type of donor defined as related or unrelated and compatibility defined as HLA
100% compatible or haploidentical [4] [5].

A myeloablative conditioning regimen was applied for most patients except for haploidentical transplants that received a reduced intensity conditioning regimen.

The prophylactic regimen for aGVHD included the combination of cyclosporine plus methotrexate for all cases. For patients that developed aGVHD the regimen followed the guideline recommendations continuing immunosuppression with first-line methylprednisolone. For patients unresponsive to steroids, either cyclosporine or mofetil mycophenolate or mTOR inhibitors or anti-TNF antibodies were administered, taking into account the main organ affected [4] [5].

2.4. Statistic Analysis

Univariate analysis was performed to estimate the frequency of aGVHD presentation for each known risk factor. Relative risk was calculated within the studied risk factors. Chi-square and Fisher’s test were applied to evaluate the statistical significance (p-values < 0.05 were considered significant). For multivariable analyses (logistic regression), variables with parameter estimates with a p-value ≤ 0.05 in the univariate analyses were included. Statistical evaluation was carried out using the version 15 of SPSS.

3. Results

3.1. Characteristics of Patients

A total of 144 transplants were performed during the study period, the transplant indications were predominantly hematologic malignancies (47.92%), followed by solid tumors (20.14%), primary immunodeficiency diseases (18.75%), bone marrow failure (8.33%), inherited metabolic diseases (4.17%) and other diseases (0.69%). Allogeneic HSCT corresponded to the majority of procedures (115, 80%).

The allogenic HSCT indications were predominantly: hematologic malignancies (60%), primary immunodeficiency disorders (23.4%), bone marrow failure syndrome (10.4%), inherited metabolic diseases (5.2%), and other diseases (0.84%). Mean age of the patients was 7.4 years (range: 0.4 to 18.7 years).

From the overall allogeneic HSCT 41 were excluded for the final analysis (34.7%): 16 on account of primary graft failure, 12 caused by patient death during the period of aplasia, 8 for incomplete data, and 5 lost to follow-up.

The most common source of hematopoietic stem cells (HSC) was umbilical cord blood (48.8%), followed by peripheral blood from HLA matched donor (33.9%), bone marrow (7.8%), haploidentical peripheral blood (3.4%), and haploidentical peripheral blood plus umbilical cord blood (1.7%) (Figure 1).

3.2. Univariate and Multivariate Analysis

Peripheral blood represents the highest risk factor for the development of aGVHD and in its comparison with bone marrow with the values of (OR 12.3
Figure 1. Allogeneic hematopoietic stem cell transplantation distribution (n = 115).

p < 0.001 and 6.2 p < 0.001 respectively) higher, however, it was possible to confirm the objective of the in the univariate analysis, CMV infections in the recipient (OR 4.11 p < 0.03) had significant value, whereas infections in the 3 months previous to allogeneic transplantation were significant in the multivariate analysis (OR 4.5 p < 0.003). That the CMV infection was repeated with a significant result (4.68 p < 0.03) (Table 1). Other classic risk factors already referred to in the literature, such as the high cellular dose and the female and male recipient donor, were of significant value in our analysis.

It also draws attention, that umbilical cord blood was significant (0.15 p < 0.001) as a protective factor to reduce the development of aGVHD.

The final analysis included 74 patients, of which 27 developed aGVHD (36.4%). Median time to aGVHD presentation was 82 days (9 to 273 days). Most patients developed grade III aGVHD, followed by grade II, IV and I (Figure 2).

The affected organs were: single presentation (skin 3.7%, and gastrointestinal 7.4%), double presentation skin and gastrointestinal (7.4%), and triple presentation (skin, liver, gastrointestinal 74%). Most patients with allogeneic HSCT were male, still, most of the patients that developed aGVHD were female. Further aGVHD patient characteristics are summarized in Table 2.

Eight patients with aGVHD died (29.6%): 3 deaths were caused directly by aGVHD 3 (37.5%), and 5 (62.5%) were secondarily caused by severe infections following the allogeneic HSCT (Table 3).

4. Discussion

Over time, several risk factors have been reported for the development of aGVHD, the frequency of presentation is variable and depends on the characteristics of the group analyzed. One of the important points is that our analysis shows that the incidence of aGVHD in our institution is 31%, that is within the
Table 1. Univariate analysis adjusted by risk factor.

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Patients with aGVHD and risk factor</th>
<th>OR</th>
<th>95% CI</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peripheral blood</td>
<td>23</td>
<td>6.25</td>
<td>2.39 - 16.28</td>
<td>0.001</td>
</tr>
<tr>
<td>Bone marrow</td>
<td>1</td>
<td>0.9</td>
<td>0.90 - 9.04</td>
<td>0.7</td>
</tr>
<tr>
<td>umbilical cord</td>
<td>3</td>
<td>0.15</td>
<td>0.45 - 0.53</td>
<td>0.001</td>
</tr>
<tr>
<td>Total body irradiation</td>
<td>10</td>
<td>1.96</td>
<td>0.76 - 5.03</td>
<td>0.12</td>
</tr>
<tr>
<td>Infection 3 months prior to allogeneic transplant</td>
<td>8</td>
<td>2.4</td>
<td>0.84 - 6.78</td>
<td>0.84</td>
</tr>
<tr>
<td>HLA-matched unrelated</td>
<td>1</td>
<td>1.1</td>
<td>0.20 - 6.06</td>
<td>0.64</td>
</tr>
<tr>
<td>HLA-non-matched unrelated</td>
<td>4</td>
<td>1.66</td>
<td>0.44 - 6.19</td>
<td>0.32</td>
</tr>
<tr>
<td>Donor/recipient Female/male</td>
<td>9</td>
<td>2.58</td>
<td>0.94 - 7.10</td>
<td>0.05</td>
</tr>
<tr>
<td>Bacteremia within the first 7 days post-transplant, n</td>
<td>12</td>
<td>1.38</td>
<td>0.57 - 3.35</td>
<td>0.3</td>
</tr>
<tr>
<td>CMV infection in the recipient</td>
<td>4</td>
<td>4.11</td>
<td>0.85 - 19.68</td>
<td>0.03</td>
</tr>
</tbody>
</table>

Table 2. Acute GVHD patient characteristics.

<table>
<thead>
<tr>
<th>HSC Source</th>
<th>Peripheral Blood</th>
<th>Umbilical Cord</th>
<th>Bone Marrow</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients</td>
<td>23</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Age, y.m (range)</td>
<td>9.6 (0.5 - 18.7)</td>
<td>5.3 (0.4 - 13.2)</td>
<td>17.4</td>
</tr>
<tr>
<td>Sex, Male/female</td>
<td>16/7</td>
<td>42737</td>
<td>0/1</td>
</tr>
</tbody>
</table>

Underlying disease, n
- Hematologic malignancies: 16
- Primary Immunodeficiency Diseases: 6
- Other: 1
- Total-body irradiation: 8
- Donor/recipient Female/male: 9
- Cell dose (Mean)
  - Peripheral Blood: 9 × 10^6/kg (2.5 - 14.6)
  - Umbilical Cord: 8.8 × 10^6/kg (4.4 - 13.3)
  - Bone Marrow: 1.48 × 10^6/kg
- Infection 3 months prior to allogeneic transplant, n: 7
- Donor, n
  - HLA-identical related: 14
  - HLA-matched unrelated: 0
  - HLA-identical unrelated: 1
  - Haploidentical: 4
- Bacteremia within the first 7 days post-transplant, n: 10
- CMV infection in the recipient n: 4
reported incidence. However, the presentation in our institute is in the lower limit, this could be explained on account that most of the allogeneic HSCT procedures were from umbilical cord (53%), a source that has a lower risk for aGVHD development (OR: 0.15; p < 0.001) [1] [2] [3] [4] [5].

The most commonly reported risk factors are also present in our analysis: peripheral blood > bone marrow (OR 12.3; p < 0.001), cell dose > 8.3 × 10⁶/kg (OR 7.1; p = 0.05) [4] [5].

One of the first studies to analyze the associations between infections and aGVHD is the study by Poutsiak et al., the analysis included 218 patients, in this report it is reported that in the multivariate analysis, the infections that occur at the beginning of the conditioning and the first 10 days are a risk factor for developing aGVHD grade 2 or higher (HR 2.1 p < 0.02) [6].

In the most recent report, especially in the pediatric population, Sano et al., conducted a retrospective study with 301 patients, at pediatric age, where report that HLA mismatched donor transplants and early stage blood stream infections (0 to 30days) (HR 4.870, p < 0.001) and (HR = 3.010, p = 0.001) respectively, which is why they are considered as a risk factor for the development of aGVHD grades III-IV [3].

In our study, we analyzed the infections that occurred in the patients but with a time of 3 months prior to the procedure to allogeneic HSCT (OR 4.5 p < 0.003), and was an important risk factor for aGVHD. In the two previously reported
studies as in ours, the cause for what is thought is the aGVHD is the activation of the T cells of the donor by the host antigen presenting cells [6]. Main bacterial infections within the population studied included: *S. aureus* and *P. aeruginosa*.

With respect to CMV infection in the recipient defined by seropositivity or positive viral load, we found that in the univariate (OR 4.11 p < 0.003) and multivariate analysis (OR 4.68 p < 0.03) it is significant and acts in an independent manner for the development of aGVHD, but it is controversial that in the study by Poutsiaka *et al.*, CMV infection has no value as a risk factor and even acts as a reduction factor for aGVHD (HR 0.45 p < 0.008) [6].

However, recently Jaing *et al.*, reported in a population of 290 pediatric patients, which had CMV infection, had statistical significance to develop aGVHD grade III and IV in the univariate analysis and is an independent factor in the multivariate (OR 11 p < 0.001), which provides support for our results, since both studies were performed in the pediatric population [2].

Mexico has an emerging market economy that presents a high incidence of infectious diseases that characterize developing nations, those coexist with chronic diseases, characteristic of developed countries. Therefore, approximately 80% of the adult population has serologic positivity to CMV without developing the disease. However, when the immunity is affected there is a possibility of developing subclinical or clinical manifestations of the disease. Concurrently, within the same epidemiological background, bacterial infections are a frequent cause of morbidity in patients with hematologic disease and immunodeficiency disorders prior to allogeneic HSCT [7].

It is well known that gastrointestinal damage inflicted by the conditioning regimen allows for bacterial products translocation (lipopolysaccharides) that co-stimulate the immune response, acting as a risk factor for development of aGVHD.

The institutional protocol for the recipient, regarding CMV infection, within the required laboratory analysis includes the antigenemia assay for detecting PP65 antigen in polymorphonuclear leukocytes and/or the viral CMV load by RT-PCR (positive > 1000 copies/mL). It has been reported that there is a relationship between the GVHD in the gastrointestinal (GI) tract and CMV GI disease. Cho *et al.* highlight that the presence of GI symptoms due to CMV infection has to be identified and treated, as CMV GI disease negatively affects GVHD survival [8].

On the other hand, Saadi *et al.* reported that there are costimulatory molecule gene polymorphisms that relate to aGVHD, including CTLA, CD28, ICOS and PD-1; with a statistically significant association between CD28 + 17 C/T and CTLA4-1661 A/G genotypes to CMV active infection in allogeneic HSCT patients that developed GVHD, compared to those that not developed GVHD [9] [10]. Still, more studies are warranted to study the validity of these costimulatory gene polymorphisms associations.

Other studies report that CMV infection is associated to immune-mediated diseases that accompany the development of chronic GVHD following allogene-
ic HSCT. The latter is due to the production of specific antibodies against CD13 during the course of CMV disease [11].

Boström et al. report that seropositive CMV analysis in recipients and donors was a risk factor for developing chronic GVHD [12].

Our study has also limiting, the first is that it is a retrospective study, with patients treated with various conditioning and antimicrobial prophylaxis schemes, and we did not evaluate the patients who had infection from the moment of infusion (day or) and its subsequent evolution, for which it is convenient to carry out a new analysis with a prospective cohort and in a multi-institutional way, since the current report is based on a single institution, another one of the limitations was that we did not evaluate the presence of infections with mortality related to transplantation, as reported in other studies.

5. Conclusion

Either bacterial infection or CMV infection in the recipient was significant risk factor within the aGVHD recipients; it is important to consider these factors for patients that are going to receive an allogeneic HSCT.

Acknowledgements

This research wasn’t supported by any foundation or donor. We thank our colleagues from National Institute of Pediatrics (INP) who provided insight and expertise that greatly assisted the research.

Conflicts of Interest

The study did not have a conflict of interest, all patients undergoing transplantation did so under informed consent and the present study was approved by the institutional research and ethics committees.

References


